AMPH vs DVA: fair value comparison
Amphastar Pharmaceuticals, Inc. and DaVita Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, AMPH currently sits closer to the top of our ranking by discount to fair value. AMPH carries the stronger quality grade.
| AMPH | DVA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $25.87 | $179.25 |
| 12-month range | $16.87–$29.40 | $103.87–$240.96 |
| Rank by discount to fair value | #27 of 108 Healthcare | #29 of 108 Healthcare |
| Quality grade | B | C |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Contracting |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: AMPH fair value analysis · DVA fair value analysis